Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Participants 18-65 years old, inclusive * BMI of 25 - 40, inclusive * Stable body weight for two months * Participants must be capable of giving signed informed consent * Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical study procedures * Willing to comply with contraception requirements Exclusion Criteria: * History of significant medical conditions and malignancy * Uncontrollable hypertension * History of alcoholism or drug addiction within 1 year prior to Screening * Current or recent participation in an investigational clinical trial * Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption